stockrowAmgen Inc.
AMGN Healthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.
- Revenue
- +8.45%
- EPS
- +19.4%
- Free cash flow
- −0.16%
- Total debt
- −1.06%
Quarter to September 2026, against a year earlier
Follow AMGN
Alert me
Amgen Inc. (AMGN) Return on assets
Amgen Inc.'s return on assets over the twelve months to 30 September 2026 was 10.1%, up 1.6 percentage points from fiscal 2025 (8.45%). Over the past ten years it has ranged from 2.51% (fiscal 2017) to 12.4% (fiscal 2019); the current reading is higher than 36% of that period. That is above the Drug Manufacturers General industry median of 2.28% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 8.45% | 4.12 |
| FY2024 | 4.33% | (3.95) |
| FY2023 | 8.28% | (2.10) |
| FY2022 | 10.4% | 0.88 |
| FY2021 | 9.50% | (2.34) |
| FY2020 | 11.8% | (0.60) |
| FY2019 | 12.4% | 0.97 |
| FY2018 | 11.5% | 8.96 |
| FY2017 | 2.51% | (7.85) |
| FY2016 | 10.4% | 0.48 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| NVO Novo Nordisk A/S compare | 22.0% |
| AMGN Amgen Inc. | 10.1% |
| BMY Bristol Myers Squibb Company compare | 9.96% |
| AZN AstraZeneca PLC compare | 9.41% |
| NVS Novartis AG compare | 8.94% |
| ABBV AbbVie Inc. compare | 7.32% |
| PFE Pfizer Inc. compare | 1.95% |
| MRK Merck & Co., Inc. compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −7.03% |
| Drug Manufacturers General industry median | 2.28% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on AMGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement